110 related articles for article (PubMed ID: 14556934)
1. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.
Gallo D; Giacomelli S; Ferlini C; Raspaglio G; Apollonio P; Prislei S; Riva A; Morazzoni P; Bombardelli E; Scambia G
Eur J Cancer; 2003 Nov; 39(16):2403-10. PubMed ID: 14556934
[TBL] [Abstract][Full Text] [Related]
2. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin.
Giacomelli S; Gallo D; Apollonio P; Ferlini C; Distefano M; Morazzoni P; Riva A; Bombardelli E; Mancuso S; Scambia G
Life Sci; 2002 Feb; 70(12):1447-59. PubMed ID: 11883719
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi N; Crema F; Gatti G; Pifferi G; Perucca E
Eur J Drug Metab Pharmacokinet; 1990; 15(4):333-8. PubMed ID: 2088770
[TBL] [Abstract][Full Text] [Related]
4. Comparative bioavailability of Silipide, a new flavanolignan complex, in rats.
Morazzoni P; Magistretti MJ; Giachetti C; Zanolo G
Eur J Drug Metab Pharmacokinet; 1992; 17(1):39-44. PubMed ID: 1499596
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.
Schandalik R; Gatti G; Perucca E
Arzneimittelforschung; 1992 Jul; 42(7):964-8. PubMed ID: 1329780
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of silipide and silymarin in rats.
Morazzoni P; Montalbetti A; Malandrino S; Pifferi G
Eur J Drug Metab Pharmacokinet; 1993; 18(3):289-97. PubMed ID: 8149949
[TBL] [Abstract][Full Text] [Related]
7. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
[TBL] [Abstract][Full Text] [Related]
8. Protective activity of silipide on liver damage in rodents.
Conti M; Malandrino S; Magistretti MJ
Jpn J Pharmacol; 1992 Dec; 60(4):315-21. PubMed ID: 1287266
[TBL] [Abstract][Full Text] [Related]
9. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
10. A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.
Lazzeroni M; Guerrieri-Gonzaga A; Gandini S; Johansson H; Serrano D; Cazzaniga M; Aristarco V; Puccio A; Mora S; Caldarella P; Pagani G; Pruneri G; Riva A; Petrangolini G; Morazzoni P; DeCensi A; Bonanni B
Cancer Prev Res (Phila); 2016 Jan; 9(1):89-95. PubMed ID: 26526990
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex.
Comoglio A; Leonarduzzi G; Carini R; Busolin D; Basaga H; Albano E; Tomasi A; Poli G; Morazzoni P; Magistretti MJ
Free Radic Res Commun; 1990; 11(1-3):109-15. PubMed ID: 2074043
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers.
Gatti G; Perucca E
Int J Clin Pharmacol Ther; 1994 Nov; 32(11):614-7. PubMed ID: 7874377
[TBL] [Abstract][Full Text] [Related]
14. Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration.
Xiao X; Yang M; Xiao J; Zou J; Huang Q; Yang K; Zhang B; Yang F; Liu S; Wang H; Bai P
Cancer Chemother Pharmacol; 2014 Apr; 73(4):807-18. PubMed ID: 24638862
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
16. Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein.
Yin G; Tang D; Dai J; Liu M; Wu M; Sun YU; Yang Z; Hoffman RM; Li L; Zhang S; Guo X
Anticancer Res; 2015 Jun; 35(6):3193-207. PubMed ID: 26026079
[TBL] [Abstract][Full Text] [Related]
17. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn CR; Kettenacker R; Griffin DW
J Vet Pharmacol Ther; 2007 Apr; 30(2):132-8. PubMed ID: 17348898
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin.
Scambia G; De Vincenzo R; Ranelletti FO; Panici PB; Ferrandina G; D'Agostino G; Fattorossi A; Bombardelli E; Mancuso S
Eur J Cancer; 1996 May; 32A(5):877-82. PubMed ID: 9081370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
